Artia Global Partners’s Soleno Therapeutics SLNO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-50,000
Closed -$2.31M – 59
2025
Q4
$2.31M Buy
+50,000
New +$2.74M 0.33% 37
2025
Q2
– Sell
-100,000
Closed -$7.14M – 45
2025
Q1
$7.14M Buy
+100,000
New +$4.87M 1.81% 15

Artia Global Partners's SLNO Position: Q2 2026 in Review

Artia Global Partners sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 68,490 shares — an estimated $2.29M sold.

Artia Global Partners first reported a position in SLNO in Q1 2024 and held it in 9 quarters. The position peaked at $45.4M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Artia Global Partners reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Artia Global Partners sold 68,490 Soleno Therapeutics shares in Q2 2026, an estimated $2.29M.
  • Artia Global Partners first reported a position in Soleno Therapeutics in Q1 2024 and held it in 9 quarters.
  • Artia Global Partners's Soleno Therapeutics position peaked at $45.4M in Q3 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Artia Global Partners's 13F filing for Q2 2026, filed 14 Aug 2026.